North Estonia Medical Centre: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
--> | --> | ||
== [[North Estonia Medical Centre OECI Criteria Compliance]] == | |||
== [[Trials]] == | == [[Trials]] == | ||
Revision as of 20:21, 21 November 2022
The North Estonia Medical Centre is one of the top healthcare providers in the country. Its statutes states that their goal is "to provide high-quality, specialized medical care and ambulance services, to be the learning base of training that precedes and follows the acquiring of health care professionals’ qualifications and does healthcare-related study and research work."
North Estonia Medical Centre OECI Criteria Compliance
Trials
Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Summary: This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
Sponsor, manager, or home institution: Agenus Inc.
Intervention/Treatment: Drug: AGEN2034
Number of patients: 211 participants
Beginning Date: April 7, 2017
Last Update: November 3, 2022
Recruitment Status: Completed.
Cancer areas of interest: Advanced Cancer and Cervical Cancer
Summary: This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.
Sponsor, manager, or home institution: Merck Sharp & Dohme LLC
Intervention/Treatment: Drug: Pembrolizumab; Radiation: Conventional Radiotherapy (Bladder only); Radiation: Conventional Radiotherapy (Bladder and pelvic nodes); Radiation: Hypofractionated Radiotherapy (Bladder only); Drug: Cisplatin; Drug: Fluorouracil (5-FU); Drug: Mitomycin C (MMC); Drug: Gemcitabine; Drug: Placebo to Pembrolizumab
Number of patients: 636 participants
Beginning Date: January 27, 2020
Last Update: October 21, 2022
Recruitment Status: Recruiting.
Cancer areas of interest: Urinary Bladder Neoplasms
Experts
Learning Resources
Patient School
Content Type: E-courses and lectures.
Target Audience: For everyone.
"Chest Cabinet"
Content Type: Local support for concerns on breast cancer.
Target Audience: Women of all ages.
Learning Resources for Relatives and Caretakers
Content Type: Guides and counseling appointment information.
Target Audience: Patients, Relatives and Caretakers.
Other Learning Materials
Patient Advisory Council
Primary Purpose: To ensure the interests of the patient are being taken into account when making decisions and designing services, and that the patient has an active role in the treatment process.
Members: Estonian Rheumatism Association; Avitus NGO; Estonian Inflammatory Bowel Disease Society NGO; Estonian Celiac Society; Estonian Psoriasis Association; Estonian Hemophilia Society; Estonian Chamber of Disabled People; Tallinn Chamber of Disabled People; Saaremaa Cancer Society; Läänemaa Cancer Association; Estonian Stroke Patients Society.
